<DOC>
	<DOCNO>NCT01303367</DOCNO>
	<brief_summary>U.S. Food Drug Administration ( FDA ) country issue warning off-label use antipsychotic demented patient behavioral psychological symptom dementia ( BPSD ) ( FDA warning , 2003 ; 2005 ; 2008 ) . There significant increase mortality rate 1.6 fold due cardiovascular event aspiration pneumonia demented patient receive antipsychotic compare placebo group . However , prescription rate antipsychotic demented patient still increase 20 % several alert Canada ( Valiyeva et al. , 2008 ) .</brief_summary>
	<brief_title>Medication Management Care Demented Patients With Behavioral Psychological Symptoms Dementia Taiwan : A Retrospective Pilot Study</brief_title>
	<detailed_description>Cumulative observation indicate demented patient withdrawn antipsychotic may exacerbate BPSD . The DART-AD study show demented patient with/without antipsychotic six month significant difference cognitive symptom BPSD ( Ballard et al. , 2008 ) . Moreover , result long-term follow-up DART-AD study demonstrate survival rate demented patient antipsychotic low without antipsychotic 24th month ( group vs. without group = 40 % vs. 71 % ) 36th month ( group vs. without group = 30 % vs. 59 % ) , respectively ( Ballard et al. , 2009 ) . Recently , several study indicate antidepressant citalopram milnacipran might new medication management demented patient BPSD ( Pollock et al. , 2007 ) . The present study design retrospective open-label pilot study . The initial research goal study determine prevalence psychotropic agent demented patient Taiwan National Health Insurance Research Database ( NHIRD ) ( 2005 v.s . 2008 ) prescription rate psychotropic agent demented patient Taipei Medical University-Teaching Hospitals ( 2002 2010 ) . The psychotropic agent define antipsychotic , antidepressant , sedative-hypnotic , anticonvulsant agent . Moreover , second objective study investigate risk cardiovascular aspiration pneumonia . Finally , result study could use create best practical protocol treatment BPSD demented patient Taiwan improve drug safety quality life . Currently , treatment BPSD , pharmacists recommend physician decrease off-label use antipsychotic demented patient BPSD . The main reason due fact off-label use antipsychotic increase significantly mortality rate demented patient . The therapeutic management BPSD base evidence-based medicine patient safety .</detailed_description>
	<mesh_term>Dementia</mesh_term>
	<criteria>This study plan study patient dementia ( ICDcode : 290.XX ) , Alzheimer 's disease ( ICDcode : 331.0 ) , and/or organic psychotic condition ( chronic ) ( ICDcode : 294.XX ) , include delirium , delusion , depressive feature , and/or condition classify elsewhere behavior disturbance . This study include demented patient mild moderate cognitive impairment ( minimental state examination [ MMSE ] = 1024/ Clinical Dementia Rating [ CDR ] = 0.52 ) . The present proposal exclude patient primary history schizophrenic disorder ( ICDcode : 295XX ) bipolar disorder ( 296XX ) .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Dementia</keyword>
	<keyword>behavioral psychological symptom dementia</keyword>
</DOC>